The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) is a huge mover today! About 93,358 shares traded hands or 36.02% up from the average. CARDIOME PHARMA CORP (NASDAQ:CRME) has declined 41.38% since April 5, 2016 and is downtrending. It has underperformed by 43.34% the S&P500.
The move comes after 8 months positive chart setup for the $56.60M company. It was reported on Nov, 7 by Barchart.com. We have $6.18 PT which if reached, will make NASDAQ:CRME worth $73.01 million more.
Analysts await CARDIOME PHARMA CORP (NASDAQ:CRME) to report earnings on November, 11. They expect $-0.21 EPS, up 32.26% or $0.10 from last year’s $-0.31 per share. After $-0.37 actual EPS reported by CARDIOME PHARMA CORP for the previous quarter, Wall Street now forecasts -43.24% EPS growth.
CARDIOME PHARMA CORP (NASDAQ:CRME) Ratings Coverage
Out of 4 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Cardiome Pharma Corp has been the topic of 7 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Brean Capital with “Buy” on Friday, March 11. The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) has “Buy” rating given on Wednesday, June 1 by H.C. Wainwright. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) has “Hold” rating given on Wednesday, October 12 by Mackie. The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) earned “Buy” rating by Zacks on Tuesday, August 11. As per Friday, August 14, the company rating was reinitiated by LB Securities. Mackie upgraded the stock to “Speculative Buy” rating in Friday, May 6 report.
According to Zacks Investment Research, “Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.”
Insitutional Activity: The institutional sentiment increased to 1.56 in 2016 Q2. Its up 0.93, from 0.63 in 2016Q1. The ratio is positive, as 4 funds sold all CARDIOME PHARMA CORP shares owned while 5 reduced positions. 6 funds bought stakes while 8 increased positions. They now own 12.02 million shares or 5.19% less from 12.67 million shares in 2016Q1.
Royal National Bank & Trust Of Canada accumulated 15,816 shares or 0% of the stock. Art Advisors Limited last reported 0% of its portfolio in the stock. Putnam Invs Limited Co owns 2.88M shares or 0.04% of their US portfolio. Alphaone Investment Services Ltd Limited Liability Company holds 1.1% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME) for 580,365 shares. Westfield Capital Mgmt Lp, a Massachusetts-based fund reported 3.91 million shares. Clarivest Asset Mgmt Ltd holds 21,187 shares or 0% of its portfolio. Deutsche Commercial Bank Ag holds 0% or 400 shares in its portfolio. Wells Fargo Mn, a California-based fund reported 700 shares. Citadel Advisors Ltd Llc has 16,077 shares for 0% of their US portfolio. Fmr Ltd Company, a Massachusetts-based fund reported 627,363 shares. Clough Capital Prtn L P has invested 0.56% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Pnc Financial Svcs Group, a Pennsylvania-based fund reported 35,580 shares. Walleye Trading holds 0% or 5,100 shares in its portfolio. Moreover, Rock Springs Capital Mngmt Limited Partnership has 0.45% invested in CARDIOME PHARMA CORP (NASDAQ:CRME) for 1.20 million shares. The New York-based Renaissance Technologies Limited Liability Co has invested 0% in CARDIOME PHARMA CORP (NASDAQ:CRME).
More news for CARDIOME PHARMA CORP (NASDAQ:CRME) were recently published by: Marketwatch.com, which released: “Cardiome Pharma Corp.” on December 21, 2009. Quotes.Wsj.com‘s article titled: “News Cardiome Pharma Corp.CRME” and published on February 12, 2011 is yet another important article.
CRME Company Profile
Cardiome Pharma Corp. (Cardiome), incorporated on March 1, 2009, is a specialty pharmaceutical company. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s divisions are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.